Member Info for Lakshmi888

Hey Firwood:)

Just think Retail isn't 'sexy' enough for many but not a problem for me;) More interested in the fundamentals and nothing screaming 'high risk' or 'beware' at me here...Seen too many shares in the high risk industries this wekk in the red or receiving bad news so this on'es a good play as far as Im concerned...

It's risen nice and steady from the mid-60s ish and Im happy with small, steady incremental daily rises that hold.

Look in from time to time and happy to leave alone for time being.....

Quietly confident that any +ve update/news in coming weeks/months will re-rate this.....

GL:)

Sanction, shmanctions....it doesn't matter....

Oil has lost over 2% now.....

Dollar hitting commods hard now......Keep on rallying the indices and something, somewhere is eventually going to give.......

Gold back under $1210. Again...........

The saga continues.........

https://www.bloomberg.com/news/videos/2018-08-07/musk-tweets-he-could-take-tesla-private-at-420

$72 billion!!! Cripes............

PS Stoopid Presenter shd have said 'Private' not 'Public'. She's obv'y well aversed.....

#Not...........

Tomie, feel free to ask me but truth is my opinion holds as much or as little credibility as anyone's in that no-one can predict the future!!

As you've asked though, No, I don't think it will breech £10.00 or near.....but what do I know hey?!;)

Remember, in May when they were awaiting data, the sp was approx £8.50+ and it cld have easily gone into double figures at that time as it wld only have required a 17-18% gain.

At this level, you wld need an 8 bagger minimum and that's on assumption this sp level holds...

In addition, the drug can't in the ST-MT be licensed for Europe due to CT3 failing for the European arm of the trials....and that is quite significant Im afraid whichever way you look at it.

Sure, they can repeat it...but that takes a *lot* of ££££ and time....

In addition, a decent pipeline is the heart of any pharma and FARN's isn't all that outstanding in truth.

The Clevegen RNS is now 6 wks old yet is part of the reason for the past 2 sessions' gains.....??

Sentiment has a lot to account for on AIM for *any* share.......;) GL Tomie.

Indices are going higher!! :((((

1000000000%.

Why??

Cos Gartman just said they will fall :((

#UltimateContrarianIndicatior lmao!

https://www.bloomberg.com/news/videos/2018-02-12/gartman-says-recent-volatility-indicative-of-a-market-peak-video

Seriously though, Im just kidding ....;) Hoping for indices to fall....ST.......but asides yday, higher highs, bullishness etc though on low volume.

Dble top for SPX and then.....??

A case of when rather than if one hopes....

GL to you too and you're not a dreamer. In time, with the other drugs, cthey cld turn thinsg around bu got there work cut out re T in Europe Im afraid and as we both agree.

No point posting over there as just get attacked by most lol!;) Flipping heck, why do we do it to ourselves?!

Got the other one on my watchlist so let me know when CT news/details comes out. ATB:)

No problem Tomie;)

Ultimately any drug passing CT3 is what matters for potential patients ..watching or in a number myself which would be life changing for certain conditions which dont currently have any cure/treatment/drug....

Which is the other drawback re pharma ie the lengthy timescales! :(

ATB and GL :)

As said this morning, slowly, slowly.... :D

Remains uder the radar so no unncessary pump and dump, spiking etc. Steady gain on daily basis soon adds up...

Already up approx 20% from recent lows....

All good here :)))

Tomie, can't answer that; no-one knows how much it is worth.

And the magic word is *IF*. That's the point with any pharma isn't it...... *IF* they pass CT3....and why it's literally red or black;)

And hence why pharma is such a different beast to Oilies etc.....

Any drug passing CT3 to any pharma is a major milestone, but equally as we saw with Traumakine, if it fails, then as seen the share can drop from £8.50+ to 50p in weeks.....

Additionally, Japanese data still doesn't overcome the issue with EMA licensing...and CT3 is very costly....

Unfort'y, I cant see into the future though it seems most on LSE apparently can, lol!

As said, I will continue to trade any share if I feel there is a decent x% gain to be had but without ramping or deramping & without maming unfounded 'predictions' so I'll leave the *actual* worth to the relevant bodies/companies. Leave you guys to it now. GL:)

Tomie, best of luck :)

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=SML&ArticleCode=ucyjv7e3&ArticleHeadline=Executive_Director_Appointment&ahc=jck1mnda

Y-Alm, no worries;)

I traded this at low 50s for a 50%+ gain and ever since, as and when I cld spot a potential x% gain, but without the need for ramping/deramping etc ....

Sure I intercept when it's obvious some have hidden agendas and/or are spouting nonsense either b/c they've been spiked or for their own selfish gains or when posting outright fiction.

Truth is *no-one* knows where it is going. Directors bought at ~£8 prior to data being released and it duly tanked so they too didn't anticipate CT3 failure...they bought a no. of times since and it continued to drop significanly so anyone stating anything abt 'inside info' needs to have a serious word with themselves;)

Those claiming there is a leak re Japanese data haven't got a clue and no-one will know what it is until an RNS is released....

I will trade if I feel there is a trade to be had as I do with any share but what I won't do is post ramping nonsese or fiction re the trials, data, drugs etc....

Wideyed remains the most credible poster on this bb imho....but what is amusing is that pis get so defensive if anyone posts a contrarian or factual pov. Why? Is that not allowed?!

If the data is good, one cld see a decent rise but not back to £8.50+ ST. If CT3 for Japan is inferior or shows failure, this cld hit new lows.....Who knows?!

Everything else currently is supposition or surmisation on most pis part imho.... How many have done any research at all yet jump on pis stating facts?!

Anyhow, GL Y-Alam/All :)

Mister Positive never heard such tosh?/ You should have! You post enough of it in every share you ramp up and then leave...

If you're going to repeat what I said, try some honesty and do it in context i.e I wrote ''c.f CT3''. Funny how you take what you want and post select parts!!

But then you only spout what suits you for your own gains....lol!!

#Transparent

Mr Positive, you have your objectives so let's leave it at that.

Plenty have said it's going to £8.50. I didnt state 'overnight'.

I've researched this share more than most and warbned many when it was at under £2.00 it was going to drop and more importantly *WHY* rather than just deramping, It then dropped to 50p.

I havent just jumped in this morning so grant me a little credit ; it's you claiming earlier it was oversold.

Well it dropped another 60+% from levels of awhen the data first came out so it wsn't oversold and in pharma, it can;t be 'oversold'. If the drug doesn't work, it's worthless.

The fact there may be others in the pipeline is an entirely separate issue.

ATB.

Hi Y-Lam, Im not misinformed. Worked in the industry ;)

CT3 is the pivotal one and of those reaching that stage, it is CT3 where they are likely to fail at and why it is so costly to pharma....

CT2 is almost a confirmation phase and without dismissing it, holds little significance c.f CT3 which is also more accurate and repesentative due to the higher no of patieints companies need to enroll....

Fact is CT3 failed its objectives and the data did not show patients wld benefit; in fact more patients on the placebo survived that those taking the drug albeit a small % difference.

That wldn't be accepted by any Medical Agency anywhere in the world Im afraid....hence the need to repat if the wish EMA to accept it and get a license for Europe...

Dont shoot the messenger, lol! GL:)

Sorry Itsallamess, I didnt realise pis could only post on bbs if they simply ramp a share rather than stating facts and objective points of view.

Missed that 'rule'!! ;)

Hi Wideyed. Lol, not a lot has changed;)

Some still claiming today the drop was 'oversold' a few months ago without even having researched *why* the drop happened....hey ho!

This is tradeable, sure no denying that, but anyone claiming they know this going back to £8.50+ etc and/or what the outcome of the Japan data is going to be is talking utter nonsense. Pis also need to look back as to why it dropped previously..

Each to their own.....

GL with your holding here; good to see even though you hold, you remain objective and dignified! I really hope it comes good for you :D

Wideyed, yes, FARN cant license Traumakine in Europe as EMA wld outrightly reject it due to CT3 failing few months back.

FARN would need to undertake CT3 right from the beginning irrespective of what the Japanese trial data is in order to gain a license for Europe...

There's an awful lots of 'ifs', 'possibility', 'possible', 'could' in the CEO's statement.

Plus it is *only* CT2, not the pivotal CT3 and that's the one one that really matters. Most drugs/novel compounds make it through CT2 so it's never as significant as CT3. It's CT3 many fail at....

Just look at it from a balanced, objective pov....

Wideyed, agree.;)

slowly, catchy monkey................ ;)